For two decades, independent pharmacies, employers, and patients have waited for legislation to fix what the Big 3 PBMs have broken. We have watched the hearings. We have read the FTC interim reports. We have celebrated bills that died in committee and applauded executive orders that changed nothing. Caremark, Express Scripts, and OptumRx still control more than 80 percent of the prescription drug market. They still profit from spread pricing. They still retain rebates that belong to plan sponsors. They still steer patients to pharmacies they own. They still set reimbursement terms that close one independent pharmacy every day.
The legislation is theater. The hearings are theater. The press releases are theater. Nothing changes because nothing is built to change it. The Big 3 have lobbyists, PACs, and revolving-door relationships that ensure every reform bill arrives at the finish line either gutted or dead. Anyone still waiting for Congress to save independent pharmacies and self-funded employers from PBM extraction is waiting for a bus that is not coming.
A new battle needs fought. And it needs fought now, by the people who actually have something at stake.
This is asymmetric warfare. The Big 3 are not going to lose because a Senate subcommittee shames them. They are going to lose because pharmacies, employers, brokers, and fiduciary PBMs stop participating in the system that funds them.
Here Is What That Looks Like
Independent pharmacies stop accepting reimbursement terms designed to kill them. The Big 3 reimburse their own pharmacies at one rate and competing independents at another. They impose DIR fees, retroactive clawbacks, and network terms that make survival mathematically impossible. Independents cannot out-lobby CVS Health. They can refuse contracts that lose them money. They can align with fiduciary PBMs and TPAs that pay fair acquisition-cost-plus reimbursement. They can organize regionally to negotiate as blocks. Every independent that joins a transparent network and refuses a predatory one is a node the Big 3 cannot extract from.
Employers stop signing contracts they cannot read. Every self-funded employer has a fiduciary duty under ERISA to act in the sole interest of plan participants. The J&J case made it explicit: if you signed a PBM agreement with spread pricing, undisclosed rebate retention, and mandatory mail-order steering, you did not discharge your fiduciary duty. You delegated it to an entity whose business model depends on breaching it. The remedy is not waiting for Congress. The remedy is reading the contract, demanding fixed PMPM pricing with zero spread and 100 percent rebate pass-through, and walking away from any PBM that will not provide it.
Brokers and consultants stop earning override commissions from the entities they are supposed to evaluate. The dirty secret of the benefits industry is that many brokers receive undisclosed compensation from the same PBMs they recommend to clients. This is not a regulatory problem waiting on legislation. It is a fiduciary problem solvable today. Brokers who disclose all compensation, charge their clients directly, and recommend PBMs on the merits become the immune system of the employer market.
Fiduciary PBMs stop trying to look like the Big 3 and start being something the Big 3 cannot become. This is the heart of the asymmetric strategy. We are not smaller versions of Caremark. We are a different category. Fixed disclosed fees. Zero spread. Full rebate pass-through. Open networks. Independent pharmacy parity. Clinical decisions made by clinicians, not by formulary committees serving rebate maximization. The Big 3 cannot match this structure without dismantling the business model that makes them profitable.
The Terrain Is the Contract
This is the terrain we choose. Not the Senate floor. Not the press cycle. The actual contracts. The actual claims. The actual pharmacies. The actual patients.
The Big 3 are built for a fight that is not happening. They have scale, capital, and political access designed to defeat reform legislation and competitor PBMs trying to play their game. They are not built to fight an exodus. They are not built to fight pharmacies organizing regionally. They are not built to fight employers exercising fiduciary duty one renewal at a time. They are not built to fight a coalition of fiduciary PBMs, TPAs, and clinical partners moving faster than their account management cycles.
We do not need a federal bill. We need a renewal cycle. Every January 1 and July 1, billions of dollars in PBM contracts come up. Every one of them is a battle. Every one of them is winnable on the merits if the pharmacy, the employer, the broker, and the fiduciary PBM are aligned and willing to do the work.
Appro-Rx was built for this fight. So are a small number of other fiduciary operators who refused to take the spread, refused to keep the rebates, and refused to steer patients away from the independent pharmacies that serve their communities. We are not waiting for the next FTC report. We are not waiting for a hearing where a senator looks stern and accomplishes nothing.
We are fighting now. Contract by contract. Pharmacy by pharmacy. Employer by employer. That is the only battle that has ever changed anything in this industry, and it is the only one that will.
The PBMs you are angry about will not be defeated in Washington. They will be defeated in the renewal meeting next quarter, when a pharmacy refuses a predatory network, when an employer reads the contract and asks the right questions, and when both sign with someone who actually works for them.
That fight is available right now. The only question is who is willing to fight it.
